Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 14 studies | 34% ± 9% | |
| endothelial cell of lymphatic vessel | 14 studies | 25% ± 7% | |
| endothelial cell | 6 studies | 21% ± 5% | |
| epithelial cell | 5 studies | 28% ± 13% | |
| cardiac muscle cell | 5 studies | 36% ± 8% | |
| type I pneumocyte | 5 studies | 21% ± 4% | |
| neuron | 4 studies | 28% ± 16% | |
| retinal ganglion cell | 4 studies | 60% ± 24% | |
| glutamatergic neuron | 4 studies | 40% ± 14% | |
| abnormal cell | 3 studies | 28% ± 10% | |
| GABAergic neuron | 3 studies | 39% ± 10% | |
| basal cell | 3 studies | 25% ± 1% | |
| transit amplifying cell | 3 studies | 21% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 32% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 1972.27 | 89 / 89 | 100% | 41.44 | 899 / 901 |
| intestine | 100% | 1266.69 | 964 / 966 | 100% | 27.49 | 526 / 527 |
| lung | 100% | 1913.79 | 577 / 578 | 100% | 31.70 | 1152 / 1155 |
| esophagus | 100% | 1346.56 | 1438 / 1445 | 100% | 24.52 | 183 / 183 |
| ovary | 100% | 1163.61 | 180 / 180 | 99% | 24.19 | 426 / 430 |
| thymus | 100% | 2408.43 | 653 / 653 | 99% | 27.07 | 599 / 605 |
| uterus | 100% | 957.72 | 170 / 170 | 99% | 34.98 | 454 / 459 |
| breast | 100% | 1715.80 | 459 / 459 | 99% | 34.89 | 1104 / 1118 |
| pancreas | 100% | 1343.20 | 327 / 328 | 99% | 22.89 | 176 / 178 |
| liver | 100% | 1586.31 | 226 / 226 | 99% | 38.78 | 400 / 406 |
| prostate | 100% | 1313.52 | 244 / 245 | 99% | 26.35 | 496 / 502 |
| stomach | 99% | 1377.16 | 357 / 359 | 99% | 23.99 | 283 / 286 |
| skin | 100% | 1715.40 | 1803 / 1809 | 97% | 31.09 | 459 / 472 |
| bladder | 95% | 1180.76 | 20 / 21 | 99% | 33.40 | 501 / 504 |
| adrenal gland | 100% | 1180.67 | 258 / 258 | 93% | 29.44 | 215 / 230 |
| brain | 94% | 1532.50 | 2482 / 2642 | 86% | 19.07 | 605 / 705 |
| adipose | 100% | 1574.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 21.82 | 29 / 29 |
| muscle | 100% | 4179.52 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2230.98 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 31.01 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 18.84 | 1 / 1 |
| blood vessel | 99% | 1064.11 | 1318 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 6630.90 | 848 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 94% | 21.01 | 75 / 80 |
| peripheral blood | 59% | 717.41 | 546 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0007507 | Biological process | heart development |
| GO_0043516 | Biological process | regulation of DNA damage response, signal transduction by p53 class mediator |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0006338 | Biological process | chromatin remodeling |
| GO_0018026 | Biological process | peptidyl-lysine monomethylation |
| GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
| GO_0018027 | Biological process | peptidyl-lysine dimethylation |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0016278 | Molecular function | lysine N-methyltransferase activity |
| GO_0000993 | Molecular function | RNA polymerase II complex binding |
| GO_0016279 | Molecular function | protein-lysine N-methyltransferase activity |
| GO_0002039 | Molecular function | p53 binding |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0140999 | Molecular function | histone H3K4 trimethyltransferase activity |
| GO_0140938 | Molecular function | histone H3 methyltransferase activity |
| GO_0046975 | Molecular function | histone H3K36 methyltransferase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SMYD2 |
| Protein name | N-lysine methyltransferase SMYD2 (EC 2.1.1.354) (Histone methyltransferase SMYD2) (SET and MYND domain-containing protein 2) SMYD2 protein SET and MYND domain containing 2 N-lysine methyltransferase SMYD2 (EC 2.1.1.-) (HSKM-B) (Histone methyltransferase SMYD2) (EC 2.1.1.354) (Lysine N-methyltransferase 3C) (SET and MYND domain-containing protein 2) |
| Synonyms | KMT3C |
| Description | FUNCTION: Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1. Specifically trimethylates histone H3 'Lys-4' (H3K4me3) in vivo. The activity requires interaction with HSP90alpha. Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'. . FUNCTION: Protein-lysine N-methyltransferase that methylates both histones and non-histone proteins, including p53/TP53 and RB1. Specifically trimethylates histone H3 'Lys-4' (H3K4me3) in vivo. The activity requires interaction with HSP90alpha. Shows even higher methyltransferase activity on p53/TP53. Monomethylates 'Lys-370' of p53/TP53, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity of p53/TP53. Monomethylates RB1 at 'Lys-860'. . |
| Accessions | I6L9D1 Q05C86 Q9NRG4 ENST00000366957.10 [Q9NRG4-1] B0R0U3 ENST00000416415.2 |